NIH trial to test antibodies and other therapeutics for mild, moderate COVID-19

(NIH/National Institute of Allergy and Infectious Diseases) A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease. Researchers sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are working with clinical sites to identify potential patient volunteers currently infected with SARS-CoV-2, the virus which causes COVID-19, who have mild to moderate disease not requiring hospitalization.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news